Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PLRX Pliant Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: PLRX
Price (delayed)
$1.46
Market cap
$89.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.47
Enterprise value
$76.93M
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual
Highlights
The company's quick ratio fell by 38% YoY but it rose by 6% QoQ
The revenue has dropped by 100% year-on-year
PLRX's gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of PLRX
Market
Valuations
Earnings
Shares outstanding
61.24M
Market cap
$89.4M
Enterprise value
$76.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$228.37M
Net income
-$210.3M
EBIT
-$207.28M
EBITDA
-$201.7M
Free cash flow
-$159.35M
Per share
Balance sheet
Liquidity
EPS
-$3.47
EPS diluted
-$3.47
Free cash flow per share
-$2.63
Book value per share
$5
Revenue per share
$0
TBVPS
$6.56
Total assets
$396.95M
Total liabilities
$92.87M
Debt
$60.19M
Equity
$304.08M
Working capital
$329.05M
Debt to equity
0.2
Current ratio
10.91
Quick ratio
10.75
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.5%
Return on equity
-56.8%
Return on invested capital
-51.9%
Return on capital employed
-57%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLRX stock price
How has the Pliant Therapeutics stock price performed over time
Intraday
2.1%
1 week
-9.88%
1 month
19.18%
1 year
-89.11%
YTD
-88.91%
QTD
8.15%
Financial performance
How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$228.37M
Net income
-$210.3M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% year-on-year
PLRX's gross profit has dropped by 100% year-on-year
The net income has contracted by 30% YoY and by 4.3% from the previous quarter
PLRX's operating income is down by 24% year-on-year and by 2.8% since the previous quarter
Price vs fundamentals
How does PLRX's price correlate with its fundamentals
Growth
What is Pliant Therapeutics's growth rate over time
Valuation
What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 26% year-on-year and by 3.9% since the previous quarter
PLRX's price to book (P/B) is 89% lower than its 5-year quarterly average of 2.7 and 86% lower than its last 4 quarters average of 2.1
The equity has contracted by 36% YoY and by 12% from the previous quarter
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Pliant Therapeutics business performance
The ROE has dropped by 82% year-on-year and by 16% since the previous quarter
Pliant Therapeutics's return on assets has shrunk by 57% YoY and by 11% QoQ
The company's return on invested capital has shrunk by 53% YoY and by 9% QoQ
Dividends
What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLRX.
Financial health
How did Pliant Therapeutics financials performed over time
The total liabilities has soared by 141% YoY but it has contracted by 7% from the previous quarter
Pliant Therapeutics's current ratio has decreased by 38% YoY but it has increased by 6% from the previous quarter
Pliant Therapeutics's debt is 80% lower than its equity
The equity has contracted by 36% YoY and by 12% from the previous quarter
PLRX's debt to equity is up by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.